rsv/hmpv vaccine
Vaccineexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2023 (NCT06134648)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- MetapneumovirusImmunity, active
Metapneumovirus immunity, active
- RSV F-proteinImmunity, active
RSV F-protein immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07295028 | Phase 1 | Nov 17, 2025 | Emeritus Research, Veritas Research., Corp., Vicebio |
| NCT06583031 | Phase 1 | Oct 9, 2024 | Sanofi-Aventis |
| NCT06604767 | Phase 1 | Sep 17, 2024 | Sanofi-Aventis |
| NCT06134648 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2023 | Sanofi-Aventis |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi-Aventis | For profit | 3 | 3 | 2 | 2023 |
| Emeritus Research | For profit | 1 | 0 | 1 | 2025 |
| Veritas Research., Corp. | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Vicebio | For profit | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1